The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $55.16, representing a -2.56% change from its previous close.

Morningstar ( ($MORN) ) has shared an update. Morningstar, Inc. has addressed investor inquiries received up to September 30, 2025, focusing on ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

CRISPR Therapeutics is anticipated to report higher revenues but a year-over-year decline in earnings for the quarter ended September 2025, with analyst expectations suggesting a possible earnings ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

This Vanguard ETF is performing very well, but there's a highly specific reason for that -- and it should probably worry you ...

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $62.56, representing a -2.51% change from its previous close.

Detailed price information for Value ETF Vanguard (VTV-A) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals Incorporated remains a leader in CF treatments, fueling robust cash flow and pipeline expansions.

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $67.21, marking a +1.04% move from the previous day.